{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:49:31Z","timestamp":1790887771577,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40262-022-01107-4","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T02:02:20Z","timestamp":1643248940000},"page":"481-488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Scoping Review of the Clinical Pharmacokinetics of Bedaquiline"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-2512","authenticated-orcid":false,"given":"Kyle J.","family":"Wilby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"1107_CR1","unstructured":"World Health Organization. Tuberculosis. 2020. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tuberculosis. Accessed 26 Sept 2021."},{"issue":"10","key":"1107_CR2","doi-asserted-by":"publisher","first-page":"e1372","DOI":"10.1016\/S2214-109X(21)00299-0","volume":"9","author":"S Silva","year":"2021","unstructured":"Silva S, Arinaminpathy N, Atun R, Goosby E, Reid M. Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the sustainable development goals tuberculosis targets: a full-income analysis. Lancet Glob Health. 2021;9(10):e1372\u20139. https:\/\/doi.org\/10.1016\/S2214-109X(21)00299-0.","journal-title":"Lancet Glob Health"},{"issue":"11","key":"1107_CR3","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1164\/rccm.202003-0526OC","volume":"202","author":"NA Menzies","year":"2020","unstructured":"Menzies NA, Bellerose M, Testa C, et al. Impact of effective global tuberculosis control on health and economic outcomes in the United States. Am J Resp Crit Care Med. 2020;202(11):1567\u201375. https:\/\/doi.org\/10.1164\/rccm.202003-0526OC.","journal-title":"Am J Resp Crit Care Med."},{"key":"1107_CR4","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis, module 4: treatment - drug-resistant tuberculosis treatment. 2020. https:\/\/www.who.int\/publications\/i\/item\/9789240007048. Accessed 26 Sept 2021."},{"key":"1107_CR5","unstructured":"Centers for Disease Control and Prevention. Fact sheet: extensively drug resistant tuberculosis (XDR TB). 2016. https:\/\/www.cdc.gov\/tb\/publications\/factsheets\/drtb\/xdrtb.htm. Accessed 26 Sept 2021."},{"issue":"6","key":"1107_CR6","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/jam.14478","volume":"128","author":"R Singh","year":"2020","unstructured":"Singh R, Dwivedi SP, Gaharwar US, Meena R, Rajamani P, Prasad T. Recent updates in drug resistance in Mycobacterium tuberculosis. J App Microbiol. 2020;128(6):1547\u201367. https:\/\/doi.org\/10.1111\/jam.14478.","journal-title":"J App Microbiol."},{"key":"1107_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jgar.2021.02.017","volume":"25","author":"S Khoshnood","year":"2021","unstructured":"Khoshnood S, Goudarzi M, Taki E, et al. Bedaquiline: current status and future perspectives. J Glob Antimicrob Resist. 2021;25:48\u201359. https:\/\/doi.org\/10.1016\/j.jgar.2021.02.017.","journal-title":"J Glob Antimicrob Resist."},{"key":"1107_CR8","unstructured":"Centers for Disease Control and Prevention. Fact sheet: treatment of multidrug-resistant tuberculosis: bedaquiline. 2016. https:\/\/www.cdc.gov\/tb\/publications\/factsheets\/treatment\/bedaquiline.htm. Accessed 26 Sept 2021."},{"issue":"1","key":"1107_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.5588\/ijtld.19.0221","volume":"24","author":"E Dang","year":"2020","unstructured":"Dang E, Sayagh F, Le MP, Neuville M, Sinnah F, Timsit SF, et al. Plasma pharmacokinetics of bedaquiline administered by nasogastric tube in an intensive care unit. Int J Tuberc Lung Dis. 2020;24(1):110\u20132. https:\/\/doi.org\/10.5588\/ijtld.19.0221.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"9","key":"1107_CR10","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1093\/jac\/dku171","volume":"69","author":"RPG van Heeswijk","year":"2014","unstructured":"van Heeswijk RPG, Dannermann B, Hoetelmans RMW. Bedaquiline: a review of human pharmacokinetics and drug\u2013drug interactions. J Antimicrob Chemother. 2014;69(9):2310\u20138. https:\/\/doi.org\/10.1093\/jac\/dku171.","journal-title":"J Antimicrob Chemother"},{"key":"1107_CR11","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1124\/dmd.113.056119","volume":"42","author":"K Liu","year":"2014","unstructured":"Liu K, Li F, Lu J, Liu S, Dorko K, Xie W, et al. Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos. 2014;42:863\u20136. https:\/\/doi.org\/10.1124\/dmd.113.056119.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"1107_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/cid\/civ921","volume":"62","author":"OW Akkerman","year":"2016","unstructured":"Akkerman OW, Odish OFF, Bolhuis MS, et al. Pharmacokinetics of bedaquiline in cerebrospinal fluid and serum in multidrug-resistant tuberculosis meningitis. Clin Infect Dis. 2016;62(4):523\u20134. https:\/\/doi.org\/10.1093\/cid\/civ921.","journal-title":"Clin Infect Dis"},{"key":"1107_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","volume":"18","author":"Z Munn","year":"2018","unstructured":"Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18:143. https:\/\/doi.org\/10.1186\/s12874-018-0611-x.","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"1107_CR14","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1128\/AAC01418-013","volume":"58","author":"SC McLeay","year":"2014","unstructured":"McLeay SC, Vis P, van Heeswijk RPG, Green B. Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug. Antimicrob Agents Chemother. 2014;58(9):5315\u201324. https:\/\/doi.org\/10.1128\/AAC01418-013.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1107_CR15","doi-asserted-by":"publisher","first-page":"e00463","DOI":"10.1128\/AAC00463-19","volume":"63","author":"DH Salinger","year":"2019","unstructured":"Salinger DH, Nedelman JR, Mendel C, Spigelman M, Hermann DJ. Daily dosing for bedaquiline in patients with tuberculosis. Antimicrob Agents Chemother. 2019;63(11):e00463-e519. https:\/\/doi.org\/10.1128\/AAC00463-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"1107_CR16","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/psp4.12147","volume":"5","author":"EM Svensson","year":"2016","unstructured":"Svensson EM, Dosne A-G, Karlsson MO. Population pharmacokinetics of bedaquiline and metabolite M2 in patients with drug resistant tuberculosis: the effect of time-varying weight and albumin. CPT Pharmacometr Syst Pharmacol. 2016;5:682\u201391. https:\/\/doi.org\/10.1002\/psp4.12147.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"1107_CR17","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/jac\/dkaa550","volume":"76","author":"WA Alghamdi","year":"2021","unstructured":"Alghamdi WA, Al-Shaer MH, Kipiani M, Barbakadze K, Mikiashvili L, Kempker RR, et al. Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis. J Antimicrob Chemother. 2021;76:1019\u201324. https:\/\/doi.org\/10.1093\/jac\/dkaa550.","journal-title":"J Antimicrob Chemother"},{"key":"1107_CR18","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1093\/jac\/dkx317","volume":"72","author":"EM Svensson","year":"2017","unstructured":"Svensson EM, Karlsson MO. Modelling of mycobacterial load reveals bedaquiline\u2019s exposure-response relationship in patients with drug-resistant TB. J Antimicrob Chemother. 2017;72:3398\u2013405. https:\/\/doi.org\/10.1093\/jac\/dkx317.","journal-title":"J Antimicrob Chemother"},{"key":"1107_CR19","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/bcp.14199","volume":"86","author":"L Tanneau","year":"2020","unstructured":"Tanneau L, Karlsson MO, Svensson EM. Understanding the drug-exposure relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug resistant tuberculosis. Br J Clin Pharmacol. 2020;86:913\u201322. https:\/\/doi.org\/10.1111\/bcp.14199.","journal-title":"Br J Clin Pharmacol"},{"key":"1107_CR20","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1093\/jac\/dku504","volume":"70","author":"EM Svensson","year":"2015","unstructured":"Svensson EM, Murray S, Karlsson MO, Dooley KE. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new TB drug. J Antimicrob Chemother. 2015;70:1106\u201314. https:\/\/doi.org\/10.1093\/jac\/dku504.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"1107_CR21","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1128\/AAC04171-14","volume":"59","author":"H Winter","year":"2015","unstructured":"Winter H, Egizi E, Murray S, et al. Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects. Antimicrob Agents Chemother. 2015;59(2):1219\u201324. https:\/\/doi.org\/10.1128\/AAC04171-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1107_CR22","doi-asserted-by":"publisher","first-page":"e00855","DOI":"10.1128\/AAC.00855-17","volume":"62","author":"AM Healan","year":"2018","unstructured":"Healan AM, McLeod Griffiss J, Proskin HM, O\u2019Riordan MA, Gray WA, Salata RA, et al. Impact of rifabutin or rifampin on bedaquiline safety, tolerability, and pharmacokinetics assessed in a randomized clinical trial with healthy adult volunteers. Antimicrob Agents Chemother. 2018;62(1):e00855-e917. https:\/\/doi.org\/10.1128\/AAC.00855-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1107_CR23","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/cpdd.639","volume":"8","author":"AM Healan","year":"2019","unstructured":"Healan AM, Salata RA, McLeod Griffiss J, Proskin HM, O\u2019Riordan M, Gray WA, et al. Effects of rifamycin coadministration on bedaquiline desmethylation in healthy adult volunteers. Clin Pharmacol Drug Dev. 2019;8(4):436\u201342. https:\/\/doi.org\/10.1002\/cpdd.639.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"5","key":"1107_CR24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/QAI.0b013e3182410503","volume":"59","author":"KE Dooley","year":"2012","unstructured":"Dooley KE, Park J-G, Swindells S, et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculosis agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group study A5267. J Acquir Immune Defic Syndr. 2012;59(5):455\u201362. https:\/\/doi.org\/10.1097\/QAI.0b013e3182410503.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"1107_CR25","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1128\/AAC00191-13","volume":"57","author":"EM Svensson","year":"2013","unstructured":"Svensson EM, Aweeka F, Park J-G, Marzan F, Dooley KE, Karlsson MO. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother. 2013;57(6):2780\u20137. https:\/\/doi.org\/10.1128\/AAC00191-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1107_CR26","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1016\/S2352-3018(19)30035-9","volume":"6","author":"MR O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell MR, Padayatchi N, Daftary A, Orrell C, Dooley KE, Rivet Amico K, et al. Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection. Lancet HIV. 2019;6(3):e201\u20134. https:\/\/doi.org\/10.1016\/S2352-3018(19)30035-9.","journal-title":"Lancet HIV."},{"issue":"11","key":"1107_CR27","doi-asserted-by":"publisher","first-page":"6406","DOI":"10.1128\/AAC03246-14","volume":"58","author":"EM Svensson","year":"2014","unstructured":"Svensson EM, Dooley KE, Karlsson MO. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. Antimicrob Agents Chemother. 2014;58(11):6406\u201312. https:\/\/doi.org\/10.1128\/AAC03246-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"1107_CR28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.resinv.2019\/01.001","volume":"57","author":"K Tsuyuguchi","year":"2019","unstructured":"Tsuyuguchi K, Sasaki Y, Mitarai S, Kurosawa K, Saito Y, Koh T. Safety, efficacy, and pharmacokinetics of bedaquiline in Japanese patients with pulmonary multidrug-resistance tuberculosis: an interim analysis of an open-label phase 2 study. Resp Investig. 2019;57:345\u201353. https:\/\/doi.org\/10.1016\/j.resinv.2019\/01.001.","journal-title":"Resp Investig."},{"issue":"1","key":"1107_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5588\/ijtld.18.0042","volume":"23","author":"S Perrineau","year":"2019","unstructured":"Perrineau S, Lachatre M, Le MP, et al. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23(1):99\u2013104. https:\/\/doi.org\/10.5588\/ijtld.18.0042.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1107_CR30","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1111\/bcp.13696","volume":"84","author":"EM Svensson","year":"2018","unstructured":"Svensson EM, du Bois J, Kitshoff R, et al. Relative bioavailability of bedaquiline tablets suspended in water: implications for dosing in children. Br J Clin Pharmacol. 2018;84:2384\u201392. https:\/\/doi.org\/10.1111\/bcp.13696.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01107-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-022-01107-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01107-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T02:46:14Z","timestamp":1648867574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-022-01107-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1107"],"URL":"https:\/\/doi.org\/10.1007\/s40262-022-01107-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"assertion":[{"value":"4 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The author has no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"KW was the sole author of this article.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}